Estrogen is essential for growth and development of the mammary glands and has been associated with the promotion and growth of breast cancer and in line with this, most human breast cancers are initially estrogen-dependent and undergo regression when deprived of their supporting hormone. Estrogen exerts many of its effects via two nuclear estrogen receptors (ERs), ERa and ERb. The discovery of a second ER, ERb, demanded a full re-evaluation of estrogen action in all target tissues and different estrogen associated diseases, including human breast cancer. However, despite over 15 years of research, the exact role, if any, of ERb in human breast cancer remains elusive. The main challenges now are to develop highly selective anti-ERb antibodies that are applied to large well characterized human breast cancer samples to validate their diagnostic potential and to explore ERb-selective agonists in animal models of breast cancer to validate their therapeutic potential.
The discovery of a second estrogen receptor (ER), ERb, demanded a full re-evaluation of estrogen action in all target tissues and different estrogen associated diseases, including human breast cancer. However, despite over 15 years of research, the exact role, if any, of ERb in human breast cancer remains elusive and today only ERa is used in making clinical decisions and as the targeted receptor.
This review aims to review our current understanding of ERb in relation to breast cancer, what has been learnt from studying in vitro cellular models, animal models as well as clinical samples and human genetics. It is clear that ERb should be explored for its potential to stratify breast cancer diagnosis and as a target for novel therapeutic avenues particularly as only 70% of ERa positive cases respond to tamoxifen. We suggest that challenges now are to develop highly selective anti-ERb antibodies that are applied to large well characterized human breast cancer samples to validate their diagnostic potential and to explore ERb-selective agonists in animal models of breast cancer to validate their therapeutic potential.
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Introduction
Breast cancer is the second most common cancer and the most common cancer among women in the world (Parkin et al., 2005) . It is a heterogeneous disease that includes several distinct subtypes with distinctive gene expression patterns and different overall survival (Sorlie et al., 2001) . The treatment of breast cancer has been greatly advanced in the past decades due to the discovery of specific predictive and prognostic biomarkers that enable the application of more individualized therapies to different molecular subgroups with distinct clinical behavior (Sawyers, 2008) .
Studies of breast cancers using gene expression profiling have identified several major molecular subtypes, including luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) (also known as ERBB2)-overexpressing, normal breast tissue-like, and basal-like (Sorlie et al., 2001 (Sorlie et al., , 2003 . Based on immunohistochemical staining of ERa, progesterone receptor (PR) and HER2, breast cancer falls into the following subgroups;
Luminal, subtype A: ERa and PR positive, HER-2 negative, luminal, subtype B: ERa, PR and HER-2 positive, HER2 overexpression: ERa and PR negative, HER-2 positive and triple-negative breast cancer (TNBC): ERa, PR and HER-2 negative.
Estrogen signaling in the normal breast and breast cancer
Estrogen is essential for growth and development of the mammary glands and has been associated with the promotion and growth of breast cancer. In normal mammary tissue, ERb is the most widely expressed ER, and is expressed in both luminal and myoepithelial cells as well as in some cells in the surrounding stroma .
Studies of ERb knock-out (KO) (ERbKO) mice suggest a minor effect of ERb on the mammary gland as ERbKO animals undergo an overall normal mammary gland development. Subtle effects associated with decreased differentiation and increased proliferation in the alveoli of lactating mammary glands are sometimes observed in these mice. These changes appear to be age related and are only observed in some ERbKO models (Forster et al., 2002; Palmieri et al., 2002) .
Most human breast cancers are initially estrogen-dependent and undergo regression when deprived of their supporting hormone. The presence of significant amounts of ERa in breast cancer at the time of diagnosis is taken as an indication of hormone dependence (Huang et al., 2005) . On this basis, treatment with ERa antagonistic compounds, such as tamoxifen, is first line for adjuvant therapy. Introduction of ER antagonists for treatment of hormone responsive breast cancer represents a milestone in the treatment of this life threatening disease. However, ERa status is not a perfect marker for responsiveness to antiestrogens; only 70% of ERa positive cases respond to tamoxifen. Importantly, 30-40% of patients receiving adjuvant tamoxifen therapy eventually relapse. Thus, resistance to endocrine therapy is a significant clinical problem. Clearly, additional and/or complementary factors are necessary to more accurately define patients who will benefit from the above therapy and to derive novel treatment strategies. One such factor could be ERb that should be explored for its potential predictive value as well as a potential drug target.
Human ERb
The human ERb gene (ESR2) is located on chromosome 14q23.2, spanning 61.2 kb. The ERb protein is produced from eight exons. The full-length human ERb (also named ERb1) protein includes 530 amino acids with an estimated molecular mass of 59.2 kDa (Ogawa et al., 1998a) .
The ER ligand-binding domain (LBD) is composed of 12 a helices. Agonist binding, in contrast to antagonist binding, stabilizes the overall conformation of the LBD and induces a conformation that promotes co-activator binding. The ligand-binding pocket of ERb differs at only two amino acid positions to that of ERa. However, amino acid differences not directly part of the ligand-binding pocket as well as the overall smaller size of the ERb pocket may contribute to the identification of compounds displaying receptor selectivity. Some ERb selective ligands have been identified, one of the most studied is diarylpropionitrile (DPN). However, generally these ligands only display modest selectivity for ERb versus ERa and there is clearly a need to develop novel compounds with improved selectivity.
Transcription of the human ESR2 gene occurs from at least two different promoters, named promoter 0N and promoter 0K (Hirata et al., 2001) . It should be noted that full-length ERb cDNA sequences containing neither exon 0N nor exon 0K have been reported, suggesting the presence of (an) additional promoter(s). We have shown that transcripts from promoter 0N were more common than those from promoter 0K in normal breast epithelial cells and a panel of breast cancer cell lines (Zhao et al., 2003) . Further studies aimed at characterization of promoters 0K and 0N and identification and characterization of putative additional promoters should aid in defining mechanisms for how expression of the human ESR2 gene is regulated.
ERb genetic variants
Many SNPs have been described for the ESR2 gene. Importantly, none of these changes the amino acid sequence of the ERb protein.
Two commonly studied SNPs, rs4986938 and rs928554, are located in 3 0 untranslated regions of ESR2 and could affect mRNA stability and/or translatability. However, using allelic expression and luciferase assays we demonstrated that the two alleles of the respective SNPs were present at the same mRNA level and are expressed at equal protein levels in the context of luciferase constructs suggesting that the alleles of the two SNPs do not display differences with regard to mRNA stability and/or translatability (Putnik et al., 2009) .
A number of association studies have been carried out to investigate the relationship between polymorphic sites in the ESR2 gene and breast cancer risk. Overall, the results are inconclusive and few studies demonstrate significant association for a single allele. The lack of replication could reflect population based differences or limited cohort sizes. Yu et al. conducted a meta analysis for the most frequently studied SNPs, rs1256049 and rs4986938 and their association with breast cancer (Yu et al., 2011) . Women harboring the variant allele rs4986938 seemed to present with decreased risk either in the dominant model or in the co-dominant model. rs1256049 was not associated with breast cancer risk in any model. However, five studies had investigated the effect of haplotypes in the ESR2 gene on breast cancer risk, and four of them had positive outcomes. Furthermore, genome wide association studies (GWAS) have not provided evidence for an association between ESR2 and breast cancer.
In summary, there is presently no evidence that ESR2 is a major genetic determinant of breast cancer risk. However, the genetic contribution of ESR2 to breast cancer risk needs to be further explored. Particularly, a minor role of ESR2 variants in breast cancer or the role of these variants in linkage with other genes, particularly in certain types of breast cancer and in certain populations cannot be excluded. Future studies employing high throughput sequencing might reveal novel, less common, genetic variants in ESR2 associated with risk of breast cancer.
ERb splice variants
Multiple ERb isoforms exist as a result of either alternative splicing of the last coding exons (exon 8 and exon 9, respectively), deletion of one or more coding exons, or alternative usage of untranslated exons in the 5 0 region (Fig. 1 ). Among these the ERb2 variant is the best studied. ERb2 is the result of alternative splicing where the last exon of ERb1, exon 8 constituting part of the ligand-binding domain, is exchanged for an alternative exon, exon 9. The ERb2 protein differs from ERb1 in its C-terminus and encodes a protein of 495 amino acid residues with a predicted molecular mass of 55.5 kDa. ERb2 has undetectable affinity for 17b-estradiol (E2) and other tested ligands. ERb2 was suggested to be a dominant-negative inhibitor of ERa (Ogawa et al., 1998b) . Our laboratory has further investigated the possible molecular mechanism for the antagonistic effect of ERb2 on ERa-mediated transactivation. Our results show that ERb2 induces proteasomedependent degradation of ERa, presumably through the formation of ERb2/ERa heterodimers (Zhao et al., 2007) . We suggest that ERb2-mediated degradation of ERa is at least one mechanism whereby expression of ERb2 inhibits recruitment of ERa to the estrogen-responsive promoters, leading to suppression of ERa-regulated genes. Additionally, ERb4 and ERb5 isoforms were identified as truncated transcripts containing only part of the common exon 7 and different exon 8 sequences and thus will not bind ligands (Moore et al., 1998) . In vitro studies show that ERb4 and b5 can heterodimerize with ERb1 and enhance its transactivation in a ligand-dependent manner (Leung et al., 2006) .
Epigenetic regulation of ERb
Studies have demonstrated that promoter 0N is subject to regulation by DNA-methylation. Hypermethylation of the ESR2 promoter is associated with a marked decrease of ERb mRNA expression in breast tumors and breast cancer cell lines as compared to normal epithelial cells and the inhibition of DNAmethyltransferases reactivates ERb expression in these cell lines (Rody et al., 2005; Zhao et al., 2003) . The finding of ESR2 gene silencing via promoter hypermethylation predominantly in tumors with an unfavorable prognosis may indicate a role for the ESR2 gene in breast cancer development and/or growth and may be used as a prognostic molecular biomarker. Expression of ERb also seems to be regulated by histone acetylation. In both ERa-positive luminal and ERa-negative basal-like breast cancer cells histone deacetylase inhibitors (HDI) increase ERb expression (Duong et al., 2006; Jang et al., 2004; Tate et al., 2012) . In ERa-negative basal-like breast cancer cells HDI and inhibitors of DNA methyltransferases increase expression of ERa and sensitizes these cells to tamoxifen (Connolly and Stearns, 2012 ). An interesting future therapy development for both ERa-positive and ERa-negative breast cancer could be combinations of epigenetic modifier(s), tamoxifen and an ERb agonist (Hodges-Gallagher et al., 2007 , 2008 .
Molecular mechanisms of estrogen action in breast cancer cells; ERb cistromes and transcriptomes
Many studies have addressed the molecular mechanism of ERb function in breast cancer cell lines, particularly MCF-7 cells and T47D cells that express ERa. More recently such studies have explored novel developments to investigate ERb global DNA-binding regions and ERb modulated global gene expression profiles.
Human breast cancer lines that express endogenous ERb, including in the presence of ERa, have not been described. The reason why breast cancer cell lines do not seem to express ERb, at a detectable protein level, is unknown but could relate to its potential anti-proliferative action, resulting in clonal selection when establishing a breast tumor cell line. Therefore, the role of ERb in regulating gene expression, including its effect on ERa gene regulatory networks, has been studied in model systems that were engineered to express either or both ERs. Binding regions for ERb1 are partly overlapping with binding regions for ERa in MCF7 cells that are engineered to express ERb1 to a similar level as the endogenous ERa (Liu et al., 2008) . However, the binding regions for the two different receptors showed distinct properties in terms of genome landscape, sequence features, and conservation. For example, GC-rich motifs are enriched in ERb1 binding sites. Examination of the effects of ligand occupied and unoccupied ERa and ERb1 on chromatin binding highlight the dynamic interplay between the two ERs in their selection of binding sites (Charn et al., 2010) . When present alone, there was substantial overlap in binding regions between both ERs, but the number of overlapping regions decreased when both ERs were present. The presence of ERb1 had a limited effect on ERa binding to chromatin. However, ERa had a profound effect on ERb1 binding to chromatin such that, ERb1 now occupies many novel sites. This dynamic interplay provides new insight for our understanding of the mechanisms by which ERs modulate each other in target cells. With regard to gene regulation by ERb, models of action involving cooperation, as well as competition, between ERs have been proposed (Matthews and Gustafsson, 2003) . However, most studies, including studies conducted in breast cancer cells, support that ERb acts as a dominant negative regulator of estrogen signaling and demonstrate repressive effects on ERa mediated transcriptional activity when co-expressed with ERa.
To investigate the impact of ERb on gene networks controlled by ERa, a model system was created by introducing ERb1 into the ERa positive human breast cancer cell lines MCF7 (Chang et al., 2006) or T47D (Williams et al., 2008) . Gene expression profiling analysis revealed that, in this system, un-liganded ERb1 could regulate the expression of many genes that were normally regulated by estrogen through ERa, suggesting that ERb1 has a significant impact on ERa mediated gene expression. The effects of liganded ERb1 on ERa mediated gene regulation could not be studied in this system due to the lack of ligands that are strictly ERb1 selective. In this model system, the regulation of genes involved in the TGFb pathway, cell cycle progression and apoptosis may contribute to the suppression of cell proliferation observed with ERb1 expression (Chang et al., 2006) . Similarly in T47D breast cancer cells, stable overexpression of ERb1 inhibited ERa regulation of many genes (Williams et al., 2008) . ERa-induced and ERb1-repressed genes were involved in proliferation, steroid/xenobiotic metabolism and ion transport. Fig. 2 summarizes a proposed (Secreto et al., 2007) .
The role of ERb in breast cancer cell proliferation, migration and invasion
Breast cancer cells as well as cell lines in vitro, are often dependent on estrogens to proliferate. Hence, treatment of breast cancer cells with anti-estrogens leads to cell-cycle arrest or apoptosis (Lippman et al., 1976) . Breast cancer cell lines such as MCF7 and T47D are ERa positive and dependent on estrogen for cell growth.
Published data clearly demonstrate that ERb1 has an anti-proliferative function when introduced into ERa positive breast cancer cells (Strom et al., 2004) . T47D cells engineered to express ERb1 were explored to investigate the effect of ligands on breast cancer cell proliferation. E2 or the ERa-agonist propyl-pyrazole-triol (PPT) stimulated proliferation whereas the ERb-selective agonist DPN inhibited proliferation in this model (Paruthiyil et al., 2004; Sotoca et al., 2008) . The mouse mammary cell line HC11 represents an interesting model system that expresses both ERs and was used to study the role of ERa and ERb1 in cellular proliferation. Interestingly, while E2 had no effect on proliferation, the ERa-selective agonist PPT stimulated proliferation while the ERb-selective agonist DPN inhibited cell growth and induced apoptosis (Helguero et al., 2005) . We have shown that ERb2 exerts antiproliferative effects in ERa expressing MCF7 cells, probably by initiating degradation of ERa (Zhao et al., 2007) . Only a few studies have addressed the effects of ERb1 alone on proliferation. In Hs578T TNBC cells, engineered to express ERb1, estrogen treatment inhibited proliferation while expression of ERb2 had no effects on proliferation (Dey et al., 2012) .
The actual molecular changes responsible for the anti-proliferative effects of ERb1 remain to be established. As described above, gene expression profiling has revealed ERb1 regulation of groups of genes involved in proliferation. Examples of estrogen-regulated genes promoting proliferation in the presence of ERa and where the effect is inhibited by ERb1 include c-Myc (Strom et al., 2004) . As c-Myc is induced early in the cell cycle and induces additional cell cycle genes, its induction by ERa and subsequent repression by ERb1 may be associated with multiple cell-cycle regulatory events. The Cdk2 inhibitor p27Kip1, which is down regulated upon E2 treatment of ERa positive T47D and MCF7 cells, is induced in response to ERb1 expression. However, p27Kip1 is not regulated at the transcriptional level since its mRNA level does not change significantly in response to ERb1 (Hartman et al., 2009 ). Chang et al. showed that ERb1 regulated multiple components of TGFb signaling, consistent with the established role of TGFb in the suppression of breast cancer cell proliferation (Chang et al., 2006) . Transplanting ERb1 expressing breast cancer cells into the mammary tissue of SCID/beige immunodeficient mice demonstrated inhibitory effects of ERb1 on tumor growth as well as angiogenesis (Hartman et al., 2006) . In line with the inhibitory effect of ERb1 on angiogenesis, expression of the pro-angiogenic factor PDGFb was reduced at both the mRNA and protein levels when the transplanted breast cancer cells expressed ERb1.
Epithelial to mesenchymal transition (EMT) is an essential process for normal development and is implicated in cancer progression to an invasive state. EMT has been reported to promote invasion during the progression of breast carcinomas and it is considered as an essential early step in tumor metastasis. EMT is characterized by loss of cellular adhesion, which is mediated by downregulation of adhesion molecules, such as E-cadherin. It was recently shown that ERb1 inhibits EMT and invasion in TNBC cells when they grow either in vitro or in vivo in zebrafish (Thomas et al., 2012) . The inhibition of EMT correlates with an ERb1-mediated up-regulation of miR-200a/b/429 and the subsequent repression of ZEB1 and SIP1, which results in increased expression of Ecadherin.
ERb protein expression in breast cancer: correlation to clinicopathological parameters and clinical outcome
A general finding is that total ERb levels decline during breast tumorigenesis (Leygue and Murphy, 2013; Roger et al., 2001 ). Generally higher levels of ERb expression were found to be associated with the expression of good prognostic markers or better clinical outcome, usually in patients who have subsequently been treated with tamoxifen (Esslimani-Sahla et al., 2004; Gruvberger-Saal et al., 2007; Myers et al., 2004) .
Expression of ERb in breast cancer has been analyzed at the mRNA or protein level in several clinical materials. Determination of ERb mRNA levels in breast cancer tissues needs to be interpreted with caution. Samples from breast tissue might contain cells from tumor surrounding tissue. Furthermore, there is not good correlation between ERb mRNA and ERb protein levels (Fuqua et al., 2003; Omoto et al., 2002) . Finally, this assay does not allow determination of subcellular localization of ERb isoforms. Immunohistochemistry (IHC) addresses some of the above drawbacks. Furthermore, IHC is the standard assay for classifying breast tumors as ERa positive or ERa negative tumors. However, the outcome from IHC is influenced by several factors that have to be taken into account when comparing results from different studies. Such factors include protocol for tissue preparation, antibodies used and applied scoring system. Several ERb antibodies have been generated, directed to different regions of the, in breast cancer, important ERb protein isoforms ERb1, ERb2 and ERb5 (Shaaban et al., 2008 ).
Some studies have compared different ERb antibodies in IHC assays . Furthermore, one multicenter study has assayed ERb expression in breast cancer samples using two different antibodies (Carder et al., 2005) . Together, the above studies clearly demonstrated that different antibodies produce different staining patterns and that the protocols and scoring systems influence the results. Furthermore, these studies also indicated that some antibodies gave more consistent results.
Below, we only review data from studies that have used two validated antibodies detecting ERb1 or ERb2, PPG5/10 and 57/3, respectively (Tables 1 and 2 ). This excludes the large number of studies that have used antibodies directed against the N-terminal region of ERb, detecting total ERb, i.e. the important ERb protein isoforms ERb1, ERb2 and ERb5 in breast cancer. In the majority of studies referred to in Tables 1 and 2 only nuclear ERb1 and ERb2 have been scored. However, in several studies the presence of cytosolic staining has been reported but not been included in the applied scoring system. To our knowledge only one clinical study has been reported in which an antibody detecting ERb5 was used (Shaaban et al., 2008) . This study is included in Table 2 .
In general, expression of ERb has been described to be down regulated or absent from high grade breast tumors.
Clinicopathological parameters
In general, ERb1 expression correlates with ERa expression, small tumor size, low histological grade and lymph node negativity (Table 1) (Honma et al., 2008b; Marotti et al., 2010; Nakopoulou et al., 2004; Sugiura et al., 2007) and inversely correlates to HER2 expression (Marotti et al., 2010; Myers et al., 2004; Nakopoulou et al., 2004) . In a study encompassing 2170 breast cancer patients, ERb1 expression correlated to ERa expression and inversely correlated to HER2 expression. Furthermore, the absence of ERb1 expression was associated with larger tumors, higher histological grade and dissemination to lymph nodes (Marotti et al., 2010 ). Another large study, including 757 breast cancer patients, reported no correlation between ERb1 and clinicopathological parameters (Shaaban et al., 2008) . The reasons for the different outcomes in these large studies are unclear but could be due to different antibody concentrations used and different scoring systems. In conclusion, in the majority of this limited number of studies, ERb1 expression seems to be an indicator of tumors with a relatively good prognosis. However, additional studies are needed to firmly establish the relation between ERb1 protein expression as determined by IHC and clinicopathological parameters. Further (Marotti et al., 2010) Apocrine carcinomas 47 Correlated to smaller size and lower grade in infiltrating apocrine carcinoma (Honma et al., 2008b) 
ERb2
Invasive breast carcinoma 757 Nuclear ERb2 correlated to ERa expression and inversely correlated to metastasis and vascular invasion (Shaaban et al., 2008) Invasive breast carcinoma 150 Correlated to ERa expression and low histological grade (Sugiura et al., 2007) development of better and highly selective anti-ERb antibodies is likely to resolve this discrepancy and uncover unknown physiological function of ERb in breast cancer.
There are a limited number of studies using the antibody 57/3 relating ERb2 expression to clinicopathological parameters (Table 1). In the two largest studies with 757 and 150 breast cancer patients, respectively, ERb2 expression correlated positively with expression of ERa (Shaaban et al., 2008; Sugiura et al., 2007) and low histological grade (Sugiura et al., 2007) . In one study of invasive ductal carcinoma, ERb2 expression was associated with lymphovascular invasion (Bozkurt and Kapucuoglu, 2012) . In the same study ERb2 expression in ductal carcinoma in situ was not associated with any clinicopathological parameter. Thus, at present the relation of ERb2 to clinicopathological parameters is unclear and more studies are needed to conclude the value of assaying ERb2 expression in breast cancer.
Clinical outcome
In the majority of published studies ERb1 expression in different classes of breast cancer correlates with increased disease-free survival (DFS) as shown in Table 2 (Honma et al., 2008a,b; Myers et al., 2004; Nakopoulou et al., 2004; Novelli et al., 2008; Sugiura et al., 2007; Zhang et al., 2012) . Also, increased overall survival (OS) is reported in association with high ERb1 expression levels in some studies (Honma et al., 2008a; Nakopoulou et al., 2004; Sugiura et al., 2007) . However, the results are complex. In one study with breast cancer samples characterized according to molecular characteristics, i.e. luminal A, luminal B, HER2 over expressing and basal-like, ERb1 expression was correlated to increased DFS in node negative luminal A type, but decreased DFS in node positive luminal B type (Novelli et al., 2008) . In another study, ERb1 expression was strongly correlated with increased DFS in node positive primary invasive breast cancer (Zhang et al., 2012) . Some studies in Table 2 indicate important correlations between ERb and clinical outcome that deserve further investigation to reach firm conclusions. This includes the observation that ERb1 expression was correlated with increased DFS in TNBC (Honma et al., 2008a,b) and that ERb1 expression was correlated with increased DFS in postmenopausal breast cancer but not premenopausal breast cancer (Honma et al., 2008a) . Regarding the predictive value of ERb1 expression, there are too few studies to make general conclusions. In one study of familial breast cancer ERb1 expression was associated with a favorable response to adjuvant tamoxifen treatment (Yan et al., 2011) . In another study of ERa positive breast cancer, ERb1 expression was not an indicator of response to neoadjuvant treatment (Miller et al., 2006) .
The few studies reporting IHC of ERb2 expression in breast cancer samples and its correlation to clinical outcome do not reveal a consistent picture. ERb2 expression correlates to DFS in two studies (Shaaban et al., 2008; Vinayagam et al., 2007) and to OS in two studies (Shaaban et al., 2008; Sugiura et al., 2007) , but not to DFS or OS in a study of 442 patients with primary invasive breast cancer (Honma et al., 2008a) . Interestingly, in the only two studies in which subcellular localization has been quantified, cytoplasmic expression of ERb2 correlated to decreased OS (Shaaban et al., 2008; Yan et al., 2011) . Regarding predictive value of ERb2 expression, it is reported to correlate to positive response to neoadjuvant treatment (Wurster et al., 2010) and to endocrine treatment (Shaaban et al., 2008) . However, in a study of ERa positive breast cancer, the presence of ERb2 did not predict response to neoadjuvant tamoxifen treatment (Miller et al., 2006) .
In the only study in which ERb5 was analyzed, it was reported that ERb5 correlated to increased OS but only at high percentage cutoff, i.e. 65% nuclei counted had to have positive staining for ERb5.
In summary, at present IHC analysis of the expression of ERb isoforms in breast cancer has shown interesting correlations with clinicopathological parameters and clinical outcome but additional studies of clinical samples with validated protocols and antibodies are needed before firm conclusion regarding the value of determining ERb expression in clinical diagnosis can be established.
Conclusions and outlook
An understanding of the contribution of ERb and its variants for breast cancer development, prognosis and response to treatment is critical for further exploring this receptor in relation to diagnostic and therapeutic strategies. The challenge of this task is apparent as despite over 15 years of research, the exact role, if any, of ERb in human breast cancer remains elusive. This could partly relate to that ERb may have a bi-faceted role in breast cancer displaying different roles in the presence and absence of ERa. There is some support for the notion that ERb exerts anti-proliferative effects in breast cancer cells in the presence of ERa but exerts proliferative effects in the absence of ERa (reviewed in Leygue and Murphy, 2013) . Another complication arises from the fact that ERb isoforms expressed in breast cancer could have distinct effects.
Critical for further exploring ERb and its variants as diagnostic and prognostic tools in breast cancer and as a therapeutic target, is the development of standardized protocols and highly selective antibodies for the detection of ERb and its variants by IHC.
Identification of breast cancer cell lines that express ERb and/or its variants would present a significant breakthrough for future studies addressing the molecular mechanism of ERb signaling in breast cancer. However, this might present a significant challenge in relation to the supposed anti-proliferative role of ERb1.
Development of transgenic mice models that specifically express human ERb isoforms in the mammary gland might shed light on the physiological function of ERb variants. Additionally, the identification of pharmacological ligands modulating the activity of ERb2 would constitute important tools to address the function of ERb2 in cell lines and in transgenic mice expressing ERb2.
The ESR2 gene includes several polymorphic positions. However, none of these change the amino acid sequence of the ER proteins. High throughput sequencing might reveal novel rare ESR2 variants in breast cancer samples with altered functional properties. Such variants have the potential to contribute to our understanding of ERb and its variants in breast cancer.
Today only ERa is used in making clinical decisions and as the targeted receptor. The introduction of ERb in clinical practice has the potential to improve clinical diagnosis. Furthermore, compounds with receptor selective activities might provide novel therapeutic avenues. The main challenges now are to develop well characterized highly selective anti-ERb antibodies that are applied to large well characterized human breast cancer samples to validate their diagnostic potential and to explore ERb-selective agonists in animal models of breast cancer to validate their therapeutic potential.
